Clearmind Medicine (CMND) said it has enrolled the first patient for its phase 1/2a clinical trial of CMND-100, an oral drug candidate aimed at treating alcohol use disorder.
The trial is aimed at assessing the safety, tolerability, and pharmacokinetic effects of CMND-100 in potentially reducing alcohol cravings and consumption, the clinical-stage company said.
Shares of the company were up 6% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.